Skip to main content

Table 1 Results on hospitalized RVGE cases, costs and QALYs for the original study and with new hospitalization data and herd protection

From: An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”

  No vaccination Vaccination Difference
  Individuals aged <5y Individuals aged ≥5y Individuals aged <5y Individuals aged ≥5y Individuals aged <5y Individuals aged ≥5y
Number of hospitalized cases from the original study 1
Community accquired 2,817 161 353 161 2,464 0
Nosocomial 421 149 106 149 315 0
Number of hospitalized cases from the original study (including herd protection for children <5 years)
Community accquired 2,817 161 155 161 2,662 0
Nosocomial 421 149 23 149 398 0
Number of hospitalized cases using the updated hospitalization data (and herd protection for <5 years) 2
Community accquired 4,241 223 233 223 4,008 0
Nosocomial 634 207 35 207 599 0
Number of hospitalized cases using the updated hospitalization data and herd protection (for <25 years) 2
Community accquired 4,241 223 233 180 4,008 43
Nosocomial 634 207 35 167 599 40
Discounted cost and QALYs from the original study 1
Total costs (direct and indirect)3 9,663,000 6,519,000 2,074,000 6,519,000 7,589,000 0
Total QALYs 173 NA4 64 NA4 109 NA4
Discounted cost and QALYs from the original study (including herd protection for <5 years only)
Total costs (direct and indirect)3 €9,663,000 €6,519,000 €969,000 €6,519,000 €8,694,000 €0
Total QALYs 173 NA4 32 NA4 141 NA4
Discounted cost and QALYs using the updated hospitalization data (and herd protection <5 years) 2
Total costs (direct and indirect)3 €13,246,000 €6,937,000 €1,203,000 €6,937,000 €12,043,000 €0
Total QALYs 207 NA4 37 NA4 170 NA4
Discounted costs and QALYs using updated hospitalization data and herd protection (for <25) 2
Total costs (direct and indirect costs)3 €13,246,000 €6,937,000 €1,203,000 €6,833,000 €12,043,000 €104,000
Total QALYs 207 NA4 37 NA4 170 NA4
  1. 1Herd protection was not included in the base case analysis; 2Herd protection for individuals aged less than 5 years of age was included in the same way as in the scenario analysis of Rozenbaum et al. [1]; 3Costs are excluding vaccination costs; 4No utility losses were available for individuals aged 5 years and older and death was conservatively assumed to occur in individuals aged less than 5 years of age only in the absence of any reported deaths in older ages.